Abstract
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which primarily affects the respiratory tract. Combinations of drugs are used for therapeutic synergism and to prevent the emergence of drug resistant strains, but even first- or secondchoice drugs present some disadvantages, such as significant side effects and the need for long duration of treatments. Thus, new strategies for TB control and treatment are highly demanded. In this context, protein tyrosine phosphatases (PtpA and PtpB) are secreted by Mtb within the host macrophage and they have been shown to contribute to Mtb pathogenicity. The understanding of the role of these PTPs has led to interesting anti-TB drugs discovery. Here, we review the current knowledge on these two proteins as targets for novel anti-TB therapies, with particular emphasis on their mechanism of action and current advancements in developing small molecule inhibitors from natural sources.
Keywords: Tuberculosis, Mycobacterium tuberculosis, tyrosine phosphatases, PtpA, PtpB.
Current Pharmaceutical Design
Title:Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs
Volume: 22 Issue: 12
Author(s): Alessandra Mascarello, Louise Domeneghini Chiaradia-Delatorre, Mattia Mori, Hernán Terenzi and Bruno Botta
Affiliation:
Keywords: Tuberculosis, Mycobacterium tuberculosis, tyrosine phosphatases, PtpA, PtpB.
Abstract: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which primarily affects the respiratory tract. Combinations of drugs are used for therapeutic synergism and to prevent the emergence of drug resistant strains, but even first- or secondchoice drugs present some disadvantages, such as significant side effects and the need for long duration of treatments. Thus, new strategies for TB control and treatment are highly demanded. In this context, protein tyrosine phosphatases (PtpA and PtpB) are secreted by Mtb within the host macrophage and they have been shown to contribute to Mtb pathogenicity. The understanding of the role of these PTPs has led to interesting anti-TB drugs discovery. Here, we review the current knowledge on these two proteins as targets for novel anti-TB therapies, with particular emphasis on their mechanism of action and current advancements in developing small molecule inhibitors from natural sources.
Export Options
About this article
Cite this article as:
Mascarello Alessandra, Chiaradia-Delatorre Domeneghini Louise, Mori Mattia, Terenzi Hernán and Botta Bruno, Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs, Current Pharmaceutical Design 2016; 22 (12) . https://dx.doi.org/10.2174/1381612822666160112130539
DOI https://dx.doi.org/10.2174/1381612822666160112130539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Facile Microwave-assisted Synthesis of Various C5-modified Pyrimidine Pyranonucleosides as Potential Cytotoxic Antitumor Agents
Current Microwave Chemistry Enhanced Crystallizability by Protein Engineering Approaches: A General Overview
Protein & Peptide Letters The Mode of Inhibition of Mycobacterium tuberculosis Wild-Type and Isoniazid-Resistant 2-Trans-Enoyl-ACP(CoA) Reductase Enzymes by An Inorganic Complex
Anti-Infective Agents in Medicinal Chemistry Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Infectious Disorders - Drug Targets Codon Usage Biases in Alzheimers Disease and Other Neurodegenerative Diseases
Protein & Peptide Letters Genotypic Characterization of Vancomycin-Resistant Enterococcus spp. In Tertiary Center, Iran
Infectious Disorders - Drug Targets Insights on Antimicrobial Resistance, Biofilms and the Use of Phytochemicals as New Antimicrobial Agents
Current Medicinal Chemistry Psoriatic Arthritis and its Novel Therapeutics
Current Rheumatology Reviews General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews EDITORIAL: New Avenues in Controlling Infectious Diseases
Current Topics in Medicinal Chemistry Combinatorial Approaches to Iminosugars as Glycosidase and Glycosyltransferase Inhibitors
Combinatorial Chemistry & High Throughput Screening In Vitro Antimycobacterial Activity of New 7-Chloroquinoline Derivatives
Letters in Drug Design & Discovery Anti-TNF and Pouch Surgery for Ulcerative Colitis: The Ones who Blame for More Complications?
Current Drug Targets G-quadruplex DNA Aptamers and their Ligands: Structure, Function and Application
Current Pharmaceutical Design Is tRNA Binding or tRNA Mimicry Mandatory for Translation Factors?
Current Protein & Peptide Science Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Towards the Design and Development of Agents with Broad Spectrum Chemotherapeutic Properties for the Effective Treatment of HIV / AIDS
Current Medicinal Chemistry Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder)
Current Drug Discovery Technologies